4 Cancer Centers for Personalized Glioblastoma Immunotherapy

Ganesh Akunoori
1 hour ago
13 min read

Personalized immunotherapy for glioblastoma, dendritic cell vaccines, CAR-T, and neoantigen vaccines, is available primarily through clinical trials at specialized neuro-oncology centers that coordinate tissue procurement, biomarker screening, and treatment sequencing.

Key Takeaways

Personalized glioblastoma immunotherapy uses three investigational pathways: dendritic cell vaccines, CAR-T therapy, and neoantigen-based vaccines, each tailored to individual tumor mutations
Eligibility requires narrow enrollment windows (often before standard therapy), specific biomarkers (unmethylated MGMT preferred), and performance status thresholds (ECOG 0-1 or Karnofsky ≥70)
Manufacturing timelines impose 4-6 week vaccine production lags that must align with neurosurgery schedules, leukapheresis windows, and radiation + temozolomide therapy start dates
Trial coordinators at specialized centers provide transparent protocol comparisons, biomarker requirements, cost coverage details, and multidisciplinary coordination support
Multidisciplinary tumor board evaluation must occur within days of diagnosis—not after progression, to preserve access to newly diagnosed trial protocols

Understanding Personalized Immunotherapy for Glioblastoma: What Makes It Different

Personalized immunotherapy for glioblastoma is available through clinical trials at specialized centers, using three investigational pathways: dendritic cell vaccines loaded with autologous tumor antigens, CAR-T cell therapy (investigational for solid tumors), and neoantigen-based DNA or peptide vaccines tailored to individual tumor mutations. Unlike off-the-shelf checkpoint inhibitors, these approaches require patient-specific tumor tissue procurement, biomarker screening, and manufacturing timelines measured in weeks.

Three Main Personalized Immunotherapy Pathways

The pathways differ by antigen source and delivery mechanism:

Dendritic cell vaccines combine brain tumor protein antigens derived from surgically removed tumors with dendritic immune cells generated from the patient's own blood. The vaccine trains the immune system to recognize tumor-specific targets.
CAR-T cell therapy remains investigational for glioblastoma. Tumor vaccines targeting glioma include peptide vaccines, dendritic cell vaccines, and nucleic acid vaccines.
Neoantigen-based vaccines use DNA or peptide constructs designed from whole-exome sequencing of the patient's tumor, targeting mutations unique to that individual's cancer.

Why Glioblastoma Immunotherapy Requires Clinical Trial Enrollment

All three pathways remain investigational because glioblastoma's cold tumor microenvironment and immunosuppressive barriers have not yet been overcome in Phase 3 studies. Centers offering multidisciplinary tumor board evaluation and clinical trial navigation support, such as Pi Cancer Care by Dr.Bharat Patodiya coordinate access to specialized facilities where these protocols are open. Patients undergo neurosurgery to harvest tumor tissue, then wait for vaccine manufacturing before receiving the investigational therapy.

How Personalization Differs From Standard Vaccine Approaches

Genuine personalization is not marketing language, it requires biomarker thresholds, HLA typing, and autologous tissue processing that off-the-shelf therapies bypass. Neoantigen vaccines demand neoantigen load above a minimum threshold identified through genomic profiling; dendritic cell protocols need viable tumor cells harvested during resection. These manufacturing dependencies introduce 4 to 8 week timelines between surgery and first vaccination, contrasting with checkpoint inhibitors shipped from inventory. Your care team evaluates tumor mutation burden, MGMT methylation status, and prior treatment history to determine trial eligibility.

Understanding these investigational pathways reveals why eligibility screening must begin immediately after diagnosis, narrow enrollment windows dictate which patients can access personalized protocols.

Clinical Trial Eligibility: Core Requirements for Glioblastoma Immunotherapy Programs

A common assumption, that any glioblastoma patient can enroll in immunotherapy trials, misrepresents the narrow enrollment windows created by biomarker thresholds, performance status requirements, and treatment sequencing constraints. Trial coordinators apply a multidisciplinary eligibility framework to ensure patients can tolerate manufacturing timelines and maintain adequate function throughout the investigational protocol.

Disease Status and Timing Windows

The eligibility checkpoint framework proceeds in three stages:

Disease status: Newly diagnosed unmethylated MGMT vs recurrent disease, neoantigen vaccine trials typically require unmethylated tumors due to higher neoantigen burden.
Performance status: ECOG 0-1 or Karnofsky ≥70 to ensure patients tolerate leukapheresis and immune activation.
Prior treatment history and timing windows: Enrollment must occur within 6 weeks of completing radiation to align vaccine manufacturing with standard temozolomide cycles.

These constraints reflect manufacturing realities: leukapheresis occurs 2-4 weeks post-surgery, and dendritic cell vaccine production requires 4-6 weeks, creating a 10-week window that must align with radiation completion and chemotherapy initiation.

Performance Status and Biomarker Thresholds

Before contacting trial coordinators, patients can self-assess trial fit using this checklist:

Confirmed pathology: Unmethylated MGMT status preferred for neoantigen trials, with tumor tissue available for biomarker profiling.
Performance status score: ECOG 0-1 or Karnofsky ≥70 indicating ability to perform daily activities without significant assistance.
Timing since surgery/radiation: Within 2-6 weeks post-surgery for leukapheresis, and within 6 weeks post-radiation for vaccine initiation.
HLA typing and neoantigen load: Some trials require HLA compatibility and minimum neoantigen thresholds determined through tumor profiling.

Multidisciplinary Tumor Board Coordination

Trial enrollment requires proactive multidisciplinary coordination across neurosurgery, neuro-oncology, and immunotherapy teams. Neurosurgery plans tissue procurement to meet both pathology and vaccine manufacturing requirements; neuro-oncology sequences standard therapy (temozolomide + radiation) with trial timelines; and immunotherapy teams manage leukapheresis and vaccine production schedules. Pi Cancer Care by Dr.Bharat Patodiya coordinates this 48-hour tumor board review process, connecting patients with India's leading centers while navigating international patient logistics and insurance scheme access for trial-eligible candidates.

Eligibility criteria establish the patient selection framework, but protocol type determines manufacturing timelines, tissue requirements, and treatment sequencing constraints.

Comparing Immunotherapy Protocol Types: Dendritic Cell Vs Car-T Vs Tumor Vaccines

Personalized immunotherapy for glioblastoma spans multiple platforms, dendritic cell vaccines, CAR-T cell therapy, and neoantigen-based tumor vaccines, each with distinct manufacturing timelines, personalization evidence, and eligibility constraints. Choosing among these protocols requires understanding how each adapts to individual tumor characteristics and integrates with standard-of-care temozolomide and radiation.

Dendritic Cell Vaccines: Dcvax-L and Autologous Tumor Antigen Loading

Dendritic cell vaccines, exemplified by platforms like UCLA Health's autologous tumor lysate processing approach, harvest the patient's own tumor tissue during surgery, load tumor antigens onto dendritic cells ex vivo, then re-infuse them to stimulate immune recognition. This personalization is tissue-dependent: procurement requires sufficient resectable tumor volume, and manufacturing lag (typically 4-6 weeks from apheresis to product release) must be sequenced with post-surgical radiation cycles. The trial landscape remains investigational; most dendritic vaccine protocols are phase 1/2 studies, not standard-of-care options.

Car-T Cell Therapy for Glioblastoma: Investigational Status and Manufacturing

CAR-T therapy for glioblastoma is primarily investigational, contrasting sharply with FDA-approved CAR-T products for hematologic malignancies. Solid tumor microenvironment challenges, immunosuppressive infiltrates, antigen heterogeneity, limited T-cell trafficking across the blood-brain barrier, constrain response rates. Manufacturing center capacity further limits access; Pi Cancer Care by Dr.Bharat Patodiya provides thorough CAR-T cell therapy evaluation but does not offer on-site CAR-T infusion, instead coordinating referrals to specialized centers like Tata Memorial where leukapheresis-to-infusion timelines extend 4-6 weeks and approval depends on strict inclusion criteria.

Neoantigen-Based DNA and Peptide Vaccines: Personalization Evidence

Neoantigen vaccines derive personalization from whole-exome sequencing of tumor tissue paired with normal DNA, predicting patient-specific mutations, then encoding those neoantigens in DNA or peptide formulations. GNOS-PV01, a personalized DNA cancer vaccine, encodes up to 20 patient-specific neoantigens and demonstrated immune responses in all but one steroid-exposed patient, with 24-month overall survival of 33%. GAPVAC-101 used a highly personalized peptide vaccination approach, formulating two multi-peptide vaccines per patient. The evidence gap: ask trial coordinators 'What biomarker or tumor profiling data define personalized for this protocol? What is the evidence this protocol adapts to individual tumor characteristics?', distinguishing truly adaptive platforms from off-the-shelf peptide libraries.

Center	Personalized Immunotherapy Access	Treatment Format	Neuro-oncology Specialty	Clinical Trial Availability
Pi Cancer Care	CAR-T evaluation, tumor board review coordinating neoantigen sequencing and dendritic vaccine trial enrollment	Referral-facilitated trial enrollment; standard-of-care chemotherapy/radiation with multidisciplinary tumor boards	48-hour tumor board integrating neurosurgery, pathology, and immunotherapy protocol timing	Trial coordination; on-site CAR-T not available; manufacturing center referral required
Tata Memorial Centre	On-site CAR-T manufacturing at specialized centers; dendritic vaccine trials	Trial and standard-of-care with Ayushman Bharat subsidies (50-70% cost reduction)	Dedicated neuro-oncology division with neurosurgery, radiation, and immunotherapy integration	Active investigational CAR-T and vaccine trials; centralized intake with weeks-to-months waitlists
Apollo Cancer Centres	Private CAR-T referral pathways; dendritic vaccine trial participation	Private-pay standard-of-care; trial enrollment through academic partnerships	Multidisciplinary neuro-oncology teams; private imaging and pathology integration	Trial coordination via partner academic institutions; limited on-site investigational CAR-T
AIIMS Delhi	Investigational CAR-T protocols; neoantigen vaccine research collaboration	Trial enrollment and standard-of-care with government insurance coverage up to ₹5 lakh	Neuro-oncology subspecialty with tumor board case review	Phase 1/2 neoantigen vaccine trials; limited CAR-T slots

Vignette: A patient with newly diagnosed unmethylated glioblastoma underwent multidisciplinary tumor boards at Pi Cancer Care, by Dr.Bharat Patodiya coordinating neurosurgery tissue procurement for both dendritic cell vaccine processing and whole-exome sequencing for neoantigen prediction. The 4-6 week manufacturing lag between leukapheresis and CAR-T product release required sequencing with standard temozolomide cycles, illustrating how personalized immunotherapy eligibility depends not only on tumor biomarkers but on logistical coordination across surgical oncology, pathology, and apheresis centers.

Key Takeaways: CAR-T for glioblastoma remains investigational, with manufacturing center capacity and solid tumor microenvironment challenges limiting access compared to hematologic CAR-T. Dendritic cell vaccines require sufficient resectable tumor tissue and 4-6 week manufacturing windows sequenced with radiation. Neoantigen vaccines (DNA or peptide) personalize via whole-exome sequencing but vary in evidence for true adaptive targeting versus standardized peptide libraries. Ask trial coordinators for biomarker-driven eligibility criteria and manufacturing timelines before committing to a protocol.

Protocol differences translate into practical selection criteria when evaluating which cancer centers offer trial access aligned with your biomarker profile and treatment timeline.

How to Evaluate Cancer Centers Offering Glioblastoma Immunotherapy Trials

Glioblastoma remains one of the most challenging cancers to treat, and distinguishing specialized immunotherapy trial centers from institutions offering standard chemotherapy alone requires systematic evaluation. Not all centers describing 'glioblastoma immunotherapy trials' provide equally personalized protocols, autologous tumor-specific trials demand tissue procurement coordination and patient-specific manufacturing timelines, while peptide vaccine trials use shared tumor-associated antigens with less individualization.

Questions to Ask Trial Coordinators Before Enrollment

Trial coordinators at specialized centers provide transparent answers to four critical questions that reveal protocol rigor:

What biomarker or tumor profiling data define 'personalized' for this protocol? Centers conducting autologous dendritic cell or neoantigen vaccine trials require tumor tissue analysis to identify patient-specific antigens. Trials without tissue-based customization may still be valuable but are not personalized in the autologous sense.
What is the evidence this protocol adapts to individual tumor characteristics? Ask for phase 1 or 2 data demonstrating response variability based on tumor heterogeneity. Generic peptide vaccine trials targeting shared antigens (e.g. EGFRvIII) do not adapt to individual profiles.
What are the cost components covered by the trial sponsor vs patient responsibility? As demonstrated in the TVI-Brain-1 trial at the University of Kansas Cancer Center, investigational vaccine manufacturing is sponsor-covered, but standard-of-care components (surgery, radiation, temozolomide) remain patient expenses.
What is the manufacturing timeline and how does it sequence with standard therapy? Personalized vaccine production can take 4-8 weeks post-surgery; centers with integrated protocols coordinate this timeline with radiation and chemotherapy windows to avoid treatment delays.

Geographic Access: India-Based Vs International Referral Pathways

India-based patients evaluate trial sites through two pathways: domestic academic centers conducting early-phase immunotherapy studies, or international referral to US/EU sites with mature phase 2-3 protocols. The cost differential drives many international patients to consider India for clinical trial enrollment, standard glioblastoma treatment in India ranges ₹4-8 lakhs for surgery, radiation, and chemotherapy cycles, compared to significantly higher costs in Western markets.

Travel logistics for international trials require coordinating surgical tissue procurement domestically (to ensure viability for vaccine manufacturing), shipping frozen specimens to international manufacturing facilities, and planning return travel for vaccine administration cycles. Remote monitoring feasibility varies by protocol, some trials permit local imaging and lab work with results transmitted to the trial site, while others require in-person follow-up visits every 4-6 weeks.

Cost and Insurance Considerations for Clinical Trial Participation

Trial drug costs are typically sponsor-covered, but standard-of-care expenses remain patient responsibility. For glioblastoma, this includes maximal safe resection surgery (₹1.5-3 lakhs), concurrent temozolomide and radiation (₹2-4 lakhs), and adjuvant temozolomide cycles (₹1-2 lakhs). Out-of-pocket ranges depend on whether the patient's institution offers trial enrollment, academic centers with multiple active protocols may absorb coordination costs, while private hospitals may charge facilitation fees.

Insurance coverage for trial participation varies: government schemes like Ayushman Bharat cover standard-of-care components but not investigational procedures, while private insurers may deny coverage for any treatment delivered within a trial protocol. Verify coverage before enrollment to avoid unexpected expenses.

Key Takeaways: When to Pursue Trial Enrollment Vs Standard Therapy

The decision framework balances MGMT methylation status, performance status, and access to specialized trial centers:

MGMT unmethylated patients have lower temozolomide response rates, making trial enrollment more attractive when personalized immunotherapy protocols are accessible
Performance status KPS ≥70 is typically required for trial eligibility, patients with lower functional status may not tolerate vaccine-related immune activation
Access to multidisciplinary tumor boards that review trial eligibility criteria and coordinate tissue procurement timelines is key

Pi Cancer Care by Dr.Bharat Patodiya offers multidisciplinary tumor board evaluation, second-opinion facilitation, and clinical trial navigation support, coordinating referrals to trial sites offering dendritic cell, CAR-T, or neoantigen vaccine protocols. This evaluation coordination infrastructure helps patients distinguish genuinely personalized protocols from generic shared-antigen trials and navigate the cost transparency questions trial coordinators must answer before enrollment. For centers offering thorough trial evaluation support, explore resources on top hospitals for brain cancer treatment.

Evaluating trial centers reveals logistical realities: enrollment decisions must synchronize with neurosurgery dates, tissue shipment protocols, and standard therapy scheduling.

Navigating Trial Enrollment: Timing, Logistics, and Multidisciplinary Coordination

Enrollment Windows Relative to Surgery and Standard Therapy

Glioblastoma immunotherapy trials impose narrow enrollment windows that often require coordination *before* surgery, not after progression. The sequencing workflow follows this order:

Neurosurgery with tissue procurement for pathology and vaccine manufacturing
Leukapheresis 2-4 weeks post-surgery to harvest immune cells for vaccine production
Vaccine production requiring 4-6 weeks at the manufacturing facility
Initiate radiation plus temozolomide while vaccine batch is being prepared
Vaccine administration concurrent with or immediately post-radiation

This timeline means patients cannot "wait and see" after standard therapy, enrollment decisions must be made within days of diagnosis, and your care team must align neurosurgery schedules, leukapheresis appointments, and radiation planning simultaneously.

Tissue Procurement and Manufacturing Timelines

Dendritic cell vaccines require leukapheresis 2-4 weeks post-surgery, followed by a 4-6 week vaccine production lag at the trial's manufacturing facility. CAR-T manufacturing takes 4-6 weeks from leukapheresis to infusion-ready product. Shipping logistics add coordination complexity: tumor tissue must be transported from the local neurosurgery center to the trial pathology lab within 24-48 hours, and the finished vaccine batch must ship back to the infusion site on a precise schedule to match the patient's radiation completion date.

Remote Monitoring and Follow-Up Logistics

Trial protocols mandate frequent on-site visits during the initial 12-week treatment phase (often weekly for safety assessments), then transition to remote monitoring with local oncologist coordination. Pi Cancer Care by Dr.Bharat Patodiya coordinates multidisciplinary tumor board evaluation and facilitates clinical trial referrals, managing the logistic handoff between local neurosurgery teams and trial site immunotherapy coordinators. Patients enrolling from distant regions need advance planning for temporary relocation near the trial site or hybrid protocols combining on-site infusions with telemedicine follow-up.

Explore advanced brain tumor treatment options for thorough trial navigation guidance.

Pi Cancer Care's Role in Glioblastoma Immunotherapy Evaluation and Referral

Pi Cancer Care by Dr.Bharat Patodiya does not offer on-site CAR-T cell therapy or in-house dendritic cell vaccine manufacturing. The organization functions as an evaluation coordinator and clinical trial referral facilitator, connecting patients with specialized trial sites offering personalized immunotherapy protocols.

Multidisciplinary Tumor Board Evaluation Coordination

A newly diagnosed unmethylated glioblastoma patient underwent multidisciplinary evaluation through Pi Cancer Care by Dr.Bharat Patodiya: neurosurgery reviewed tissue procurement feasibility, neuro-oncology assessed biomarker profiling (MGMT, neoantigen load), and the trial navigation team identified three dendritic cell vaccine trials with open enrollment windows aligned to the patient's surgery and radiation schedule. Pi Cancer Care's treatment protocols incorporate immunotherapy, targeted therapy, and CAR-T cell therapy evaluation, coordinating neurosurgery, neuro-oncology, and immunotherapy specialist screening through multidisciplinary tumor boards.

Second-Opinion Facilitation and Trial Navigation Support

Pi Cancer Care by Dr.Bharat Patodiya coordinates biomarker profiling review (MGMT methylation, HLA typing, neoantigen sequencing), matches patients to trial sites based on protocol type (dendritic cell vs CAR-T vs neoantigen vaccine), and manages enrollment logistics. CAR-T approval and trial enrollment depend on manufacturing center capacity and strict inclusion criteria, not every referred patient proceeds to treatment. Pi Cancer Care provides transparent candidacy assessment and coordinates referrals to trial sites with open enrollment slots.

Clinical Trial Referral Network: Dendritic Cell, Car-T, and Neoantigen Vaccine Sites

Pi Cancer Care's by Dr.Bharat Patodiya referral network spans India-based academic centers (Tata Memorial Centre, AIIMS Delhi) for dendritic cell vaccine trials and international centers for neoantigen vaccine protocols. UCLA's dendritic cell vaccine trial and MD Anderson's checkpoint inhibitor studies exemplify the specialized centers Pi Cancer Care by Dr.Bharat Patodiya coordinates with, providing travel logistics support and remote monitoring coordination for patients enrolling internationally. For more context on emerging therapies, see new glioblastoma treatments.

Conclusion

Dendritic cell vaccines require leukapheresis and 4-6 week manufacturing but use autologous tumor antigens; neoantigen DNA vaccines skip leukapheresis but require tumor sequencing and neoantigen prediction, both personalize to individual tumors but through different tissue procurement workflows. Enrolling in a clinical trial before starting standard therapy maximizes eligibility windows but delays temozolomide + radiation start by 4-6 weeks for vaccine manufacturing; waiting until progression preserves standard therapy sequencing but narrows trial eligibility to recurrent-disease protocols with fewer personalized options.

As neoantigen prediction algorithms improve and manufacturing timelines compress, personalized immunotherapy may transition from academic trial centers to broader neuro-oncology practice, but for 2026, trial enrollment at specialized centers remains the access pathway.

Coordinate a multidisciplinary tumor board evaluation this week to assess your glioblastoma immunotherapy trial candidacy, including biomarker profiling (MGMT, neoantigen load) and trial site matching, using Pi Cancer Care's by Dr.Bharat Patodiiya clinical trial navigation support or your local neuro-oncology team.

Frequently Asked Questions

What is personalized immunotherapy for glioblastoma?

Personalized immunotherapy includes dendritic cell vaccines, CAR-T, and neoantigen vaccines tailored to individual tumor mutations through whole-exome sequencing. Unlike off-the-shelf checkpoint inhibitors, these encode patient-specific mutations in DNA or peptide formulations, requiring leukapheresis or tumor sequencing for customization.

How do I know if I'm eligible for a glioblastoma immunotherapy trial?

Eligibility proceeds through three checkpoints: disease status (newly diagnosed unmethylated MGMT preferred), performance status (ECOG 0-1 or Karnofsky ≥70), and timing windows requiring enrollment before or concurrent with standard therapy. Multidisciplinary tumor board evaluation coordinates neurosurgery tissue procurement with trial enrollment timelines.

What is the difference between dendritic cell vaccines and neoantigen vaccines?

Dendritic cell vaccines load autologous cells with tumor lysate via leukapheresis and 4-6 week cell culture. Neoantigen vaccines use DNA or peptides encoding tumor-specific mutations from whole-exome sequencing, requiring tumor tissue but no leukapheresis. Both personalize to individual tumors through different procurement workflows.

How long does it take to manufacture a personalized vaccine for glioblastoma?

Dendritic cell vaccine manufacturing requires 4-6 weeks post-leukapheresis, which occurs 2-4 weeks after surgery, creating an 8-10 week window. This timeline must synchronize with standard therapy start dates (radiation + temozolomide), requiring enrollment decisions before or immediately after neurosurgery.

What questions should I ask before enrolling in a glioblastoma immunotherapy trial?

Ask four critical questions: (1) What biomarker data define 'personalized' in this protocol? (2) What evidence shows this adapts to my tumor profile? (3) What costs are trial-sponsored versus patient responsibility? (4) How does manufacturing timeline fit my treatment schedule? Transparent answers reveal protocol rigor.

Does Pi Cancer Care offer on-site CAR-T or dendritic cell vaccine therapy?

Pi Cancer Care by Dr.Bharat Patodiya does not offer on-site CAR-T or in-house vaccine manufacturing. The organization functions as a multidisciplinary evaluation coordinator and clinical trial referral facilitator, connecting patients with specialized trial sites offering personalized immunotherapy protocols.

How much does participation in a glioblastoma immunotherapy trial cost?

Trial drug costs are typically sponsor-covered, but standard-of-care expenses remain patient responsibility: maximal safe resection (₹1.5-3 lakhs), concurrent temozolomide and radiation (₹2-4 lakhs), adjuvant temozolomide (₹1-2 lakhs). No fixed trial participation pricing exists, cost varies by sponsor coverage and standard-of-care components.

Sources

Personalized immunotherapy to fight deadly brain tumors - www.uc.edu (2023)
Frontiers | Vaccine therapies for glioma: clinical frontiers and potential breakthrough - www.frontiersin.org (2025)
Adding immune-boosting agent to personalized cancer vaccine supercharges the body's immune defense against malignant brain tumors | UCLA Health - www.uclahealth.org (2024)
Neoantigen-Based Personalized DNA Vaccine and Retifanlimab for the Treatment of Patients with Newly Diagnosed, Unmethylated Glioblastoma - NCI - www.cancer.gov
Best Brain Cancer Treatment in Hyderabad, India - www.pacehospital.com
Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | National Institute of Neurological Disorders and Stroke - www.ninds.nih.gov
Frontiers | IGV-001 cellular immunotherapy for newly diagnosed glioblastoma: overcoming the logistic challenge - www.frontiersin.org (2025)
Immunotherapy for glioblastoma: current state, challenges, and future perspectives - PMC - pmc.ncbi.nlm.nih.gov
Biologics - Brain Tumor | UCLA Health Jonsson Comprehensive Cancer Center - www.uclahealth.org
Frontiers | Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma - www.frontiersin.org (2020)
Immunological outcomes of a bespoke DNA cancer vaccine in glioblastoma | Nature Cancer - www.nature.com (2026)
Brain Cancer Treatment in India: 2025 Guide & Costs - drshyam.com (2025)
World-Class Brain Cancer Treatment at a Fraction of Global Costs - medserg.com
Can Immunotherapy Succeed in Glioblastoma? - NCI - www.cancer.gov (2018)
New Innovative Immunotherapy Trial Shows Promising Results for Glioblastoma | Tufts Medicine - www.tuftsmedicine.org (2026)
Personalized vaccine doubles survival time in patients with deadly brain cancer | UCLA Health - www.uclahealth.org (2011)
Can immunotherapy treat glioblastoma? Clinical trial offers hope | UT MD Anderson - www.mdanderson.org (2019)